AMPK激动剂通过调控自噬治疗阿尔茨海默病的研究进展  

Progress in AMPK Activators as the Treatment of Alzheimer's Disease through Autophagy Regulation

作　　者：张欢[1] 王政雨[1] 段文虎[2] 周金培[1] 张惠斌[1] 

机构地区：[1]中国药科大学新药研究中心,江苏南京210009 [2]中国科学院上海药物研究所,上海201203

出　　处：《药学进展》2017年第6期450-457,共8页Progress in Pharmaceutical Sciences

摘　　要：阿尔茨海默病作为一种神经系统退行性病变,是影响中老年人健康的重大疾病之一,目前尚无治愈的特效药。腺苷酸活化蛋白激酶(AMPK)作为药物靶标在治疗2型糖尿病等代谢性疾病方面得到了广泛研究,而作为治疗阿尔茨海默病的靶点,尚未得到系统性的归纳总结。通过总结AMPK激动剂通过影响细胞自噬,进而缓解阿尔茨海默病的相关机制,对近年来AMPK激动剂在治疗阿尔茨海默病方面的进展进行综述。Alzheimer＇s disease is a neurodegenerative disease that becomes one of the major causes of sufferings in seniors and whose curative medicine is still lacking. AMP-activated protein kinase （AMPK） has been widely studied as a target for the treatment of metabolic syndromes like type II diabetes, but sparsely studied for the purpose of Alzheimer＇s disease. We summarized the mechanism of AMPK activators in alleviating AD symptoms through autophagy and recent research progress in AMPK activators in the treatment of AD.

关 键 词：阿尔茨海默病 腺苷酸活化蛋白激酶 自噬 腺苷酸活化蛋白激酶激动剂 

分 类 号：R749.16[医药卫生—神经病学与精神病学]